Metformin has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent suppression of androgen signaling pathway, and alterations of insulin-like growth factor-1 (IGF-1) signaling pathways that cause the growth and proliferation of prostate cancer. This evidence concerns the gene IGF1 and Familial prostate cancer.